JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα
Tóm tắt
Từ khóa
Tài liệu tham khảo
James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera., Nature, 434, 1144, 10.1038/nature03546
Baxter, 2005, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders., Lancet, 365, 1054, 10.1016/S0140-6736(05)71142-9
Levine, 2005, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis., Cancer Cell, 7, 387, 10.1016/j.ccr.2005.03.023
Kralovics, 2005, A gain-of-function mutation of JAK2 in myeloproliferative disorders., N Engl J Med, 352, 1779, 10.1056/NEJMoa051113
Lacout, 2006, JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis., Blood, 108, 1652, 10.1182/blood-2006-02-002030
Wernig, 2006, Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model., Blood, 107, 4274, 10.1182/blood-2005-12-4824
Zaleskas
Tiedt, 2008, Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice., Blood, 111, 3931, 10.1182/blood-2007-08-107748
Akada, 2010, Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease., Blood, 115, 3589, 10.1182/blood-2009-04-215848
Marty, 2010, Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice., Blood, 116, 783, 10.1182/blood-2009-12-257063
Mullally, 2010, Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells., Cancer Cell, 17, 584, 10.1016/j.ccr.2010.05.015
Li, 2010, JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia., Blood, 116, 1528, 10.1182/blood-2009-12-259747
Vainchenker, 2011, New mutations and pathogenesis of myeloproliferative neoplasms., Blood, 118, 1723, 10.1182/blood-2011-02-292102
Quivoron, 2011, TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis., Cancer Cell, 20, 25, 10.1016/j.ccr.2011.06.003
Moran-Crusio, 2011, Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation., Cancer Cell, 20, 11, 10.1016/j.ccr.2011.06.001
Challen, 2012, Dnmt3a is essential for hematopoietic stem cell differentiation., Nat Genet, 44, 23, 10.1038/ng.1009
Dupont, 2007, The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera., Blood, 110, 1013, 10.1182/blood-2006-10-054940
Delhommeau, 2009, Mutation in TET2 in myeloid cancers., N Engl J Med, 360, 2289, 10.1056/NEJMoa0810069
Sato, 2009, Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion., Nat Med, 15, 696, 10.1038/nm.1973
Essers, 2009, IFNalpha activates dormant haematopoietic stem cells in vivo., Nature, 458, 904, 10.1038/nature07815
Kiladjian, 2011, The renaissance of interferon therapy for the treatment of myeloid malignancies., Blood, 117, 4706, 10.1182/blood-2010-08-258772
Croker, 2004, SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis., Immunity, 20, 153, 10.1016/S1074-7613(04)00022-6
Georgiades, 2002, VavCre transgenic mice: a tool for mutagenesis in hematopoietic and endothelial lineages., Genesis, 34, 251, 10.1002/gene.10161
Schnütgen, 2007, Adopting the good reFLEXes when generating conditional alterations in the mouse genome., Transgenic Res, 16, 405, 10.1007/s11248-007-9089-8
Ogilvy, 1998, Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment., Blood, 91, 419, 10.1182/blood.V91.2.419
Almarza, 2004, Regulatory elements of the vav gene drive transgene expression in hematopoietic stem cells from adult mice., Exp Hematol, 32, 360, 10.1016/j.exphem.2004.01.005
Villeval, 1997, High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice., Blood, 90, 4369, 10.1182/blood.V90.11.4369
Kiel, 2005, SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells., Cell, 121, 1109, 10.1016/j.cell.2005.05.026
Kiladjian, 2008, Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera., Blood, 112, 3065, 10.1182/blood-2008-03-143537
de Bruin, 2013, Interferon-γ impairs proliferation of hematopoietic stem cells in mice., Blood, 121, 3578, 10.1182/blood-2012-05-432906
Ogilvy, 1999, Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment., Blood, 94, 1855, 10.1182/blood.V94.6.1855
Anand, 2011, Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms., Blood, 118, 177, 10.1182/blood-2010-12-327593
Yan, 2012, Critical requirement for Stat5 in a mouse model of polycythemia vera., Blood, 119, 3539, 10.1182/blood-2011-03-345215
Mullally, 2012, Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera., Blood, 120, 166, 10.1182/blood-2012-01-402396
Catlin, 2005, The kinetics of clonal dominance in myeloproliferative disorders., Blood, 106, 2688, 10.1182/blood-2005-03-1240
Qian, 2007, Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells., Cell Stem Cell, 1, 671, 10.1016/j.stem.2007.10.008
Richards, 2003, Pivotal role of granulocyte colony-stimulating factor in the development of progenitors in the common myeloid pathway., Blood, 102, 3562, 10.1182/blood-2003-02-0593
Muller-Sieburg, 2006, The GOD of hematopoietic stem cells: a clonal diversity model of the stem cell compartment., Cell Cycle, 5, 394, 10.4161/cc.5.4.2487
Mullally, 2013, Depletion of Jak2V617F MPN-propagating stem cells by interferon-alpha in a murine model of polycythemia vera., Blood, 121, 10.1182/blood-2012-05-432989
James, 2008, The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity., Blood, 112, 2429, 10.1182/blood-2008-02-137877
Tefferi, 2012, JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths., Blood, 119, 2721, 10.1182/blood-2011-11-395228
Shide, 2011, R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm., Blood, 117, 6866, 10.1182/blood-2010-01-262535
Lin, 1998, Impairment of T and B cell development by treatment with a type I interferon., J Exp Med, 187, 79, 10.1084/jem.187.1.79
Rosenthal, 1990, Organ-specific hematopoietic changes induced by a recombinant human interferon-alpha in mice., Fundam Appl Toxicol, 14, 666, 10.1016/0272-0590(90)90292-R
Yamane, 2008, Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes., Blood, 112, 542, 10.1182/blood-2007-12-125906
Rizza, 2010, Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity., Autoimmunity, 43, 204, 10.3109/08916930903510880
Huber, 2011, Regulation of effector and memory T-cell functions by type I interferon., Immunology, 132, 466, 10.1111/j.1365-2567.2011.03412.x